Complement factor C5a in acute exacerbation of chronic obstructive pulmonary disease

Scandinavian Journal of Immunology

Volumn 71, Issue 5, 2010, Pages 386-391

  Marc, M M ^a   Kristan, S S ^a   Rozman, A ^a   Kern, I ^a   Flezar, M ^a   Kosnik, M ^a   Korosec, P ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CYTOMETRY; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRIORITY JOURNAL; SMOKING; SPUTUM LEVEL; TOTAL LUNG CAPACITY;

AGED; ANAPHYLATOXINS; COMPLEMENT C3A; COMPLEMENT C5A; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPUTUM;

EID: 77951084459     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02385.x     Document Type: Article

References (32)

1. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 173 : 71 8.
2. Pinto-Plata VM, Livnat G, Girish M et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007 131 : 37 43.
3. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000 55 : 114 120.
4. Roland M, Bhowmik A, Sapsford RJ et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001 56 : 30 5.
5. Wedzicha JA, Seemungal TA, MacCallum PK et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000 84 : 210 215.
6. Aaron SD, Angel JB, Lunau M et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 163 : 349 355.
7. Drost EM, Skwarski KM, Sauleda J et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005 60 : 293 300.
8. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005 25 : 640 646.
9. Saetta M, Di Stefano A, Maestrelli P et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994 150 : 1646 1652.
10. Maestrelli P, Saetta M, Di Stefano A et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995 152 : 1926 1931.
11. Zhu J, Qiu YS, Majumdar S et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001 164 : 109 116.
12. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000 118 : 1557 1565. (Pubitemid 32001777)
13. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003 168 : 968 975.
14. Pan ZK. Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes. Biochim Biophys Acta 1998 1443 : 90 98.
15. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001 38 : 175 187.
16. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc Am Thorac Soc 2007 4 : 247 251.
17. Fukuoka Y, Xia HZ, Sanchez-Muñoz LB, Dellinger AL, Escribano L, Schwartz LB. Generation of Anaphylatoxins by Human ]beta[-Tryptase from C3, C4, and C5. J Immunol 2008 180 : 6307 6316.
18. Huber-Lang M, Sarma JV, Zetoune FS et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006 12 : 682 687.
19. Guo RF, Ward PA. C5a, a therapeutic target in sepsis. Recent Patents Anti-Infect Drug Disc 2006 1 : 57 65.
20. Okroj M, HeinegÅrd D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med 2007 39 : 517 530.
21. Marc MM, Korosec P, Kosnik M et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 2004 31 : 216 219.
22. Kosmas EN, Zorpidou D, Vassilareas V, Roussou T, Michaelides S. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997 112 : 341 347.
23. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 1999 45 : 1190 1199.
24. Cataldo D, Foidart JM, Lau L, Bartsch P, Djukanovic R, Louis R. Induced sputum: comparison between isotonic and hypertonic saline solution inhalation in patients with asthma. Chest 2001 120 : 1815 1821.
25. Pizzichini E, Pizzichini M, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in sputum: effects of selection of sputum to minimaze salivary contamination. Eur Respir J 1996 9 : 1174 1180.
26. Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. Chest 2006 130 : 1203 1210.
27. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006 173 : 1114 1121. (Pubitemid 43726892)
28. Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005 99 : 572 579.
29. Kew RR, Ghebrehiwet B, Janoff A. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J Clin Invest 1985 75 : 1000 1007.
30. Kew RR, Gehabrehiwet B, Janoff A. Characterization of the third component of complement (C3) after activation by cigarette smoke. Clin Immunol Immunopathol 1987 44 : 248 258.
31. Kihira Y, Kobayashi J, Kitamura S. Effects of nicotine and cigarette smoke extracts on plasma level of complement C3a and C5a, thromboxane B2 and 6-keto PGF1 alpha in rabbits. Nihon Kyobu Shikkan Gakkai Zasshi 1989 27 : 1495 1501.
32. Perricone R, de Carolis C, de Sanctis G, Fontana L. Complement activation by cigarette smoke condensate and tobacco infusion. Arch Environ Health 1983 38 : 176 179.